Recent Headlines
Within Biotechnology
Dr. Mike Chan: Leading the Future of Organ-Specific Stem Cell Therapies with Revolutionary Treatments in Regenerative Medicine
Dr. Mike Chan is a global leader in regenerative medicine, transforming lives with stem cells, exosomes, and peptides. His innovative treatments regenerate tissues, restore healing, and enhance vitality. Patients experience renewed hope, improved energy, and recovery from chronic conditions. His groundbreaking work is reshaping the future of healthcare. - March 28, 2025 - Dr. Mike Chan
Thar Process and Clean Heat Technologies Integrate CO2 Heat Pump Technology to Make Supercritical CO2 Technology a Low Cost Solution
Thar Process and Clean Heat Technologies have successfully engineered, integrated and installed electric heat pumps using CO2 - R744 - as the upcycled, natural refrigerant. The technology partnership means that Thar Process' clients can benefit from lower operating costs. Thar is known for it's innovative use of CO2 for extracting flavors, fragrances, medicinal and therapeutic compounds both in it's GMP certified facility in Pittsburgh and at client sites globally. - March 24, 2025 - Thar Process
SignaBlok to Present Preclinical Data on TREM-1-Targeting Drug for the Treatment of Cancer at the American Association for Cancer Research (AACR) Annual Meeting 2025
SignaBlok will present positive preclinical data on targeting innate inflammation for the treatment of hard-to-treat cancers. In combination with standard-of-care chemotherapy, SignaBlok's new mechanism-based inhibitor of TREM-1, an inflammation amplifier, prevents cancer recurrence, improves complete response rate and survival in experimental pancreatic cancer. In combination with anti-PD-L1 treatment, it overcomes pancreatic cancer resistance to immunotherapy. - March 21, 2025 - SignaBlok, Inc.
SignaBlok to Present Preclinical Data on TREM-1-Targeting Drug at the Respiratory Innovation Summit and American Thoracic Society International Conference 2025
SignaBlok will present positive preclinical data on targeting innate inflammation for the treatment of sepsis and pulmonary diseases. In experimental sepsis, SignaBlok's new mechanism-based inhibitor of TREM-1, an inflammation amplifier, protects from death with the level of protection not declining at delayed treatment times. In pulmonary inflammation and fibrosis in rats and mice, it reduces neutrophil infiltration in the lungs and reverses fibrosis. - March 21, 2025 - SignaBlok, Inc.
ALS Therapy Development Institute Joins DataCite to Expand Access and Impact of ARC Dataset
The ALS Therapy Development Institute (ALS TDI) is pleased to announce its acceptance as a member of DataCite, a leading global organization dedicated to ensuring research is openly available and accessible across scientific disciplines. This partnership will significantly enhance the... - March 18, 2025 - ALS Therapy Development Institute
ConductScience Accepted Into NVIDIA Connect Program, Advancing AI-Driven Behavioral Neuroscience Research Solutions
ConductScience joins the NVIDIA Connect program, accelerating AI advancements in behavioral research. This collaboration enhances ConductVision, ConductInsecta, ConductNest, and GaitMaster, optimizing research on locomotion, cognition, and social behavior across species. With NVIDIA’s support, ConductScience gains access to GPU-accelerated computing, engineering resources, and training, driving innovation in neuroscience, genetics, and medicine. - March 16, 2025 - ConductScience
Cenmed and ENG Scientific Partner to Deliver High-Quality Kitting and Custom Chemical Filling Solutions
Cenmed Enterprises and ENG Scientific have expanded their partnership to enhance kitting and custom chemical filling services for laboratories, biotech companies, and healthcare institutions. By combining Cenmed’s supply chain expertise with ENG’s chemical formulation capabilities, the collaboration streamlines reagent kit production, specimen collection solutions, and bulk chemical filling. This partnership strengthens Cenmed’s ability to deliver efficient, compliant, and scalable solutions. - March 07, 2025 - Cenmed
Regenexx® Corporate Program's Dr. Mark Testa Wins the YOU Powered Symposium 2025 Most Influential Clinician in Insurance Award
The YOU Powered Symposium is the leading annual event for "bold benefits trailblazers." It brings together hundreds of benefit professionals, solution providers, clinicians, and employers to combine diverse expertise in an effort to reform the US healthcare system on behalf of every patient. - March 04, 2025 - Regenexx Corporate Program
AI MINDSystems Foundation and GenoBank.io Announce Strategic Partnership at ETHDenver to Advance Decentralized Biobanking and Healthcare Innovation
AI MINDSystems and GenoBank.io partner at ETHDenver to advance decentralized biobanking. Integrating GenoBank.io’s BioNFT™ into the AI MINDSystems Trusted Data Ecosystem™ empowers individuals with control over their biosamples via ‘lockable’ NFTs. This collaboration aims to create secure, privacy-preserving solutions for digital biology, precision health, and research, using blockchain and Web3 technologies. They also plan to launch WISDOM Networks™ for data-driven healthcare transformation. - February 28, 2025 - AI MINDSystems Foundation
Trump-Era Administration Drug Development & Outsourcing Impact Report
How Tariffs and RFK Jr.’s HHS Appointment May Shift Drug Development & Outsourcing - February 27, 2025 - Life Science Strategy Group, LLC
NuvOx Announces MHRA Approval to Commence Phase IIb Stroke Trial
NuvOx Therapeutics, Inc. (“NuvOx”) announced that The Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom in collaboration with the Research Ethics Committee has accepted the amended request for a clinical trial authorisation (CTA). This acceptance will... - February 14, 2025 - NuvOx Therapeutics
Biovenic Scripts a New Chapter to Boom Veterinary Diagnostics
Biovenic, a powerhouse in veterinary research, transforms the way to detect and manage animal diseases, spotlighting innovative animal disease diagnostic solutions that answer the rising demand for exact and precise veterinary diagnostics worldwide. - February 12, 2025 - Biovenic
DDi Released New ViSU eIFU Version for Medical Device Companies
DDi has launched an updated version of its ViSU eIFU platform, designed for medical device manufacturers to transition from traditional paper instructions to electronic formats. The platform supports regulatory compliance with global standards, including the EU MDR and FDA, while providing multi-language accessibility and an enhanced user experience. - January 17, 2025 - DDi LLC
Ales for ALS Achieves $1 Million Milestone and Expands Nationwide
Ales for ALS™, a global initiative uniting craft breweries in the fight against ALS, has reached an extraordinary milestone in 2024: raising $1 million in a single year. Supported by Yakima Chief Hops, this program has seen remarkable growth over its 13-year journey, fueled by the dedication of brewers, sponsors, and a passionate community. - January 06, 2025 - ALS Therapy Development Institute
Augie’s Quest to Cure ALS Completes $5.8 Million Commitment to Fund ALS TDI’s Translational Research Center
The ALS Therapy Development Institute (ALS TDI) is proud to announce that Augie’s Quest to Cure ALS has fulfilled its $5.8 million commitment, pledged in 2021, to advance ALS research. This transformative funding has directly supported the Augie’s Quest Translational Research Center... - December 13, 2024 - ALS Therapy Development Institute
Regenexx Announces Dr. Philippe Hernigou as New Medical Director of Clinical Research
Regenexx®, a leader in regenerative medicine and advanced orthobiologics, is proud to announce that Dr. Philippe Hernigou, a globally recognized expert in autologous cell therapy and musculoskeletal regeneration, has joined the company as its new Medical Director of Clinical Research. Dr. - December 11, 2024 - Regenexx Corporate Program
SeroRepair Announces New Office Location to Support Expansion and Growth
SeroRepair, an eye serum leader in the veterinary industry announces expansion to a new office location for increased operations, customer service, and product development, positioning the company for continued success in the veterinary industry. With an ever-growing demand for high-quality eye care products for small and large animals and a need for increasing efficiency in veterinary practices, SeroRepair has experienced significant growth over the past year. - December 10, 2024 - SeroRepair
Arizona Pharmacy Association Appoints Garet Turner as New CEO
Today, the Arizona Pharmacy Association (AzPA), the leading voice for Arizona’s pharmacy professionals, announced the appointment of Garet Turner as its new Chief Executive Officer. Turner, a seasoned management, membership and fundraising professional will take the helm on January... - December 07, 2024 - Arizona Pharmacy Association
smartDOC: Automated Content Management Now with GenAI
smartDOC – Intelligent Content Platform for Knowledge Organizations. Easily manage regulatory content with streamlined process, leverage automation and deliver faster with their enterprise document / content system. - November 11, 2024 - DDi LLC
Synaps Dx Launches Digital Cognitive Screening and Alzheimer’s Testing with BrainCheck and Clarity Health Clinics
Synaps Dx, BrainCheck, and Clarity Health introduce an innovative online Alzheimer's and cognitive health screening tool, accessible from home. Launching in Texas, with nationwide expansion planned, this telehealth solution provides families with a convenient, reliable path to early detection during National Alzheimer’s Disease Awareness Month, reducing the need for in-office visits and empowering proactive cognitive care. - November 04, 2024 - SynapsDx
Rare Disease Foundation on the Road to Gene Therapy Brings Families to Fort Lauderdale from Around the World, November 15-17
The FOXG1 Research Foundation, the parent-led organization that is radically transforming the rare disease drug development landscape, is hosting an international conference in Fort Lauderdale from November 15-17, bringing families from across the globe together to learn about gene therapy advancements for FOXG1 syndrome. A highlight includes a presentation by 20-year-old Abraham Weitzman, who, though non-speaking, shares his lived experience using an innovative communication device. - November 04, 2024 - FOXG1 Research Foundation
GlycoMira Therapeutics Receives Key Patent for First-in-Class Oncology Therapeutic
Key patent covering GlycoMira's lead compound GM-1111 adds to the Company's already strong IP portfolio. - November 04, 2024 - GlycoMira Therapeutics, Inc.
NuvOx Announces Two New Publications
Co-Founders, Dr. Evan Unger and Dr. Jennifer LH Johnson combine efforts to publish 2 journal articles that help explain how the NuvOx drug candidate - NanO2TM works. Artificial Cells, Nanomedicine, and Biotechnology published Dodecafluoropentane emulsion as an oxygen therapeutic, an article that... - October 31, 2024 - NuvOx Therapeutics
EPA Expands TSCA Registration to Full Amphi Biosurfactant Line
Locus FS is now the first US-based company authorized by the EPA to produce biosurfactants at commercial volumes under expanded TSCA registration. This includes the Locus Ingredients division's full line of Amphi sophorolipids, offering formulators USA-made, 100% bio-based alternatives to petrochemical surfactants that can be customized for cleaning, degreasing, and corrosion resistance, while meeting strict regulations. - October 25, 2024 - Locus Performance Ingredients
US EPA Approves Locus FS’ Expanded List of Biosurfactants for the Consumer and Industrial Markets
Locus Fermentation Solutions has become the first and only US-based company authorized by the EPA to produce biosurfactants at commercial volumes under expanded Toxic Substances Control Act (TSCA) registration. This approval positions Locus FS as the leading domestic producer of 100% bio-based glycolipid biosurfactants, providing formulators with scalable, eco-friendly alternatives to chemicals in agriculture, oil & gas, industrial applications, home care, personal care and more. - October 25, 2024 - Locus Fermentation Solutions
Parvus Announces First Human Subject Dosed in a Clinical Trial with PVT201, a First-in-Class Off-the-Shelf Regulatory T-cell (Treg) Inducing pMHC Nanomedicine Therapy
Parvus Therapeutics, a private clinical-stage biopharmaceutical company developing a pipeline of novel treatments for autoimmune disease announced the successful dosing of the first subject in a Phase 1/2, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PVT201 single ascending doses in healthy subjects and primary biliary cholangitis patients. - October 17, 2024 - Parvus Therapeutics U.S., Inc.
Award-Winning Cleantech Startup Joins Cummings Properties' Woburn, MA Innovation Cluster
Active Surfaces, an early-stage solar technology company, expanded from Greentown Labs' cleantech incubator in Somerville, MA to a dedicated R&D facility in Cummings Properties' Woburn, MA innovation cluster. - October 05, 2024 - Cummings Properties
CURE Pharmaceutical Appoints Raymond Watt to Board of Directors
CURE Pharmaceutical, renowned for its innovative sublingual delivery systems, is proud to announce the appointment of Raymond Watt to its Board of Directors. - October 01, 2024 - CURE Pharmaceutical, Inc.
NuvOx Pharma LLC Announces Receipt of Qualified Person’s Declaration Equivalence to UK / EU GMP for Investigational Medical Products
NuvOx Pharma LLC, a wholly owned subsidiary of NuvOx Therapeutics Inc. (together, “NuvOx”) announced that it has received a Qualified Person’s Declaration Equivalence to UK / EU GMP for Investigational Medicinal Products Manufactured outside of EU (in Third Countries) . This... - September 21, 2024 - NuvOx Therapeutics
Superior Rail & Iron Works Named First-Ever Diamond Sponsor for ALS TDI’s White Coat Affair Gala
The ALS Therapy Development Institute (ALS TDI) has announced that Superior Rail & Iron Works, Inc. will be the first-ever Diamond Sponsor for the annual White Coat Affair gala, taking place on October 5, 2024, at the Boston Sheraton. Superior Rail & Iron Works, Inc., which was the gala’s Title Sponsor last year, is continuing its support, helping ALS TDI push forward with critical research to find treatments for ALS. - September 19, 2024 - ALS Therapy Development Institute
Valis Corporation Technology Used in Large Brain Model Project
Using Quantum-Entangled Brain Organoids for Artificial Natural and General Intelligence - September 16, 2024 - Valis Corp
Sama Therapeutics and Quine Biologics Announce Collaboration to Develop Breakthrough Antibody Therapeutics for Neurological Disorders
Sama Therapeutics and Quine Biologics have partnered to develop an innovative therapy for neurological disorders, combining AI-driven platforms and advanced antibody engineering. The collaboration focuses on biologics that precisely target the central nervous system, minimizing side effects. By integrating Sama's generative AI with Quine's antibody design expertise, the project addresses unmet medical needs and advances treatments for conditions like Alzheimer’s and multiple sclerosis. - September 13, 2024 - Quine Biologics, Inc.
Microvascular Therapeutics Announce Completion of Phase 2 Study Enrollment for MVT-100
Microvascular Therapeutics (MVT), a pioneering healthcare research and development company, is pleased to announce the completion of enrollment in MVT’s Phase 2 program using its microbubble product, MVT-100, for endocardial border delineation. This study, An Ascending Dose Comparison of... - September 13, 2024 - Microvascular Therapeutics, Inc.
Huntington Study Group and HD Genetics Collaborate to Better Serve HD Gene Positive Patients
The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) are pleased to announce a strategic partnership with HD Genetics to assist patients who have tested positive for Huntington’s disease (HD) learn about and enroll in research studies. There remains a... - September 05, 2024 - Huntington Study Group
ALS Therapy Development Institute Commemorates 25th Anniversary at the Leadership Weekend in October
Taking place from October 3-5, 2024, in the Boston area, ALS TDI’s Leadership Weekend features a series of community-focused events, including an Open House at ALS TDI’s cutting-edge research lab, the ALS TDI Research Summit, and the White Coat Affair gala. - September 03, 2024 - ALS Therapy Development Institute
New Partnership: Luminoso and KAPS Group
We are delighted to announce the partnership agreement between the KAPS Group, a long-time leader in text analytics/semantic AI consulting services for enterprise data-driven solutions, and Luminoso, a leading sentiment analysis company, whose Daylight software, a powerful but easy to use sentiment analysis tool. - August 29, 2024 - KAPS Group
ICH1132 Shows Promise in Early-Stage Tumor Growth Inhibition Studies
New comparative study of ichorbio's anti-PD-1 antibody clone RMP1-14 highlights potential for optimized cancer research protocols. - August 21, 2024 - ichorbio Ltd
Huntington Study Group Announces New CEO
The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) are pleased to announce that Daniel Claassen, MD, MS, an internationally recognized Huntington’s Disease neurologist and researcher has accepted the role as the organization’s Chief Executive... - August 20, 2024 - Huntington Study Group
Guides Collective Steps in Where Traditional Therapies have Failed with a Concierge Service to Match Seekers with Psychedelic Guides
Guides Collective launches psychedelic concierge service poised to become the "BetterHelp" of the psychedelic space. With over 600+ qualified psychedelic guides in their network, they work with you to find a psychedelic modality catered to a persons specific needs and desired outcome. - August 14, 2024 - Guides Collective
Parvus Therapeutics Announces Leadership Appointments to Support Development from Preclinical Into Clinical
New Positions Enhance Parvus Capability to Execute the Translation of Multiple Drug Candidates into the Clinic. - August 06, 2024 - Parvus Therapeutics U.S., Inc.
Minus K Technology Announces Its Ninth Educational Giveaway of Vibration Isolators to U.S. Colleges and Universities
Minus K Technology announces its Educational Giveaway of Vibrations Isolators to U.S. Colleges and Universities. - August 05, 2024 - Minus K Technology Inc.
Parvus Therapeutics Has Received Orphan Drug Designation for Primary Biliary Cholangitis and Human Research Ethics Committee Approval to Begin Clinical Testing
Parvus Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to PVT201 for the treatment of Primary Biliary Cholangitis (PBC) and PVT201 has obtained Australian Human Research Ethics Committee (HREC) approval to initiate a first-in-human... - July 29, 2024 - Parvus Therapeutics U.S., Inc.
Edison Agrosciences Announces $600,000 Seed Financing Round and Addition of Industry Veteran Tom Marsh to Board of Directors
Edison Agrosciences, an industrial biomaterials company developing a sustainable domestic source of natural rubber from sunflowers, today announced the closing of a $600,000 seed financing. - July 26, 2024 - Edison Agrosciences
Leap Years®: Supports Age-Related Cognitive Decline in Dogs and Quality Time Together with Owners Through NAD+ Enrichment
Animal Biosciences Announces Peer-Reviewed Publication of a Clinical Trial to Evaluate the Slowing of Age-Related Signs in Dogs. After five years of development, clinical results are published regarding senior dog aging in a rigorous, placebo-controlled trial performed at a North Carolina State University College of Veterinary Medicine. - July 23, 2024 - Leap Years
U.S. Precision Medicine, Inc. Signs MOU to Deploy microNeb’s VIGIL Series Inhaler Technology to Enhance Absorption of Its New Drug Candidate in IND Process
U.S. Precision Medicine, Inc. (USPM) has signed a Memorandum of Understanding (MOU) to deploy microNeb's advanced inhaler technology to expedite the uptake of its new cancer drug candidate currently in the Investigational New Drug (IND) process. - July 16, 2024 - microNeb, Inc.
MC4R Agonist Drug Candidates Demonstrate Potential to Transform GLP1 Obesity Therapy
Courage Therapeutics announced new evidence of synergy between MC4R agonists and GLP1RA drugs in a paper published in the Journal of Clinical Investigation led by co-founder Dr. Roger Cone. The company has completed a drug discovery campaign to invent a best in class portfolio of MC4R agonists for obesity in order to leverage the synergy. Potential combinations with drugs such as Ozempic and Mounjaro could improve side effects such as nausea and GI discomfort while driving increased weight loss. - July 16, 2024 - Courage Therapeutics
SYNAPS Dx Welcomes Renowned Alzheimer’s Researcher, Dr. Donna Wilcock, to Its Scientific Advisory Board
SYNAPS Dx welcomes Dr. Donna M. Wilcock, a leading Alzheimer's researcher, to its Scientific Advisory Board. Dr. Wilcock's expertise in neuroinflammation and vascular cognitive impairment will support the advancement of the DISCERN™ diagnostic test for Alzheimer's disease. This addition reinforces SYNAPS Dx’s commitment to pioneering accurate, minimally invasive diagnostics for Alzheimer's. For more info, visit SYNAPS Dx's website. - July 15, 2024 - SynapsDx
Huntington Study Group Announces Launch of LEAD-HD Observational Study
The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) today announce the release of their newest Patient Reported Outcomes (PRO) study, LEAD-HD. This observational study was developed collaboratively with the University of Rochester Center for Health +... - July 15, 2024 - Huntington Study Group
NuvOx Pharma LLC Announces Authorization of ARDS Trial from Health Canada
NuvOx Pharma LLC (“NuvOx”) announced that it has received authorization from Health Canada for its EXTEND: novEl oXygen ThErapeutic NanO2 for mild respiratory distress in Phase Ib and ARDS in Phase II Trials. Evan Unger, MD, CEO of NuvOx, said, “Acute Respiratory Distress... - July 12, 2024 - NuvOx Therapeutics
Abel Womack CEO Announces His Retirement and Successor
After 50 years with Abel Womack, John Croce, CEO retires. - June 27, 2024 - Abel Womack Inc